UNSPSC 51314101: Donetidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C20H25N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E9730RXS4H, chemically known as 5-((1,2-dihydro-2-oxo-4-pyridyl)methyl)-2-((2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)amino)-4(1h)-pyrimidinone but generally known as donetidine, which bears US NIH Compound Identifier 57484. European Medicines Agency schedules Donetidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06363MIG.

UNSPSC 51314101 Donetidine is a Commodity code, but recent state and local procurement activity under this code does not reflect donetidine procurement. Instead, issuing bodies have tagged opportunities for naloxone, generic pharmaceuticals, and pharmacy benefit program infrastructure under this code, suggesting a mismatch between the nominal code scope and actual purchasing behavior. The code shows minimal concrete activity aligned with donetidine itself; the opportunities posted are for naloxone dispensing systems, multi-source generic pharmaceutical supply agreements, and therapeutic pharmacy program design rather than the specific pharmaceutical product named in the code.

Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to gather market intelligence before a formal RFP. The geographic spread spans Florida, Minnesota, Oregon, and Texas, with cooperative purchasing vehicles playing a significant role. This code warrants careful review—the recent activity suggests either misclassification of opportunities at point of posting or a loose application of the donetidine code to broader pharmaceutical procurement categories.